BlueWillow’s proprietary oil-in-water emulsion adjuvant technology unlocks the promise of intranasal vaccination against respiratory and sexually transmitted disease. With safety established in over 400 humans dosed in clinical trials to date, the platform is compatible with a broad range of antigen types leading to vaccines the elicit the balanced mucosal, cellular and systemic immune response needed for robust and durable protection.



Human Safety Data

Announcements and Updates